Response

We appreciated the interest of Fusco et al. in our correspondence, “Regorafenib also can cause osteonecrosis of the jaw” ( 1 ), because it allowed us to examine in depth our patient’s history and underline the importance of our findings. Previous anticancer treatment for metastatic colorectal cancer included bevacizumab. The antiangiogenic treatment was started in March 2008 as standard dose (5 mg/kg dose every 2 weeks) in combination with 5-fluorouracil and irinotecan (FOLFIRI schedule) for a total of six months, followed by 12 months of bevacizumab maintenance therapy as 7.5 mg/kg dose every three weeks. Therefore, bevacizumab therapy lasted about 18 months, and it was stopped in 2009 because of surgical resection of lung metastases.